Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vascutek Ltd.

Division of Terumo Corp.

Latest From Vascutek Ltd.

Bigger Vascular Surgery Player On The Scene With Terumo's Vascutek, Bolton Merger

Terumo has merged its two subsidiaries, Vascutek and Bolton Medical, to create a $200m-revenue player in the peripheral vascular implant scene.

Cardiovascular Surgery

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

Medical Device

Lombard Medical: At Long Last, Turning The Corner In EVAR

Lombard Medical’s early efforts to tap into the endovascular AAA market ran into problems as the company’s initial financing strategy left it with too few resources to overcome the challenges that most start-up device companies face. The company’s most recent financing, a VIPE led by UK-investor Abingworth, should see Lombard through FDA approval and launch of its novel EVAR device that is targeted at patients with high degrees of vascular tortuosity. Early clinical data show its device is performing well against competition.

Medical Device Europe

EVAR Market: Challenges, Innovation and Growth

Endovascular aortic aneurysm repair procedures account for the majority of abdominal aortic aneurysm repairs performed in the US, and total worldwide revenues from aortic endograft systems now exceed $1 billion per year. Many believe that continuing improvements in endograft technology will drive EVAR penetration to 90% or beyond within the next five to 10 years. This article first appeared in the April issue of Medtech Insight, April 2011.
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Terumo Corp.
  • Senior Management
  • Contact Info
  • Vascutek Ltd.
    Phone: (44) 41 812 5555
    Newmains Ave., Inchinnan
    Refrewshire, PA4 9RR